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Abstract 
Background: Staphylococcus aureus bloodstream infection (SAB) is a common, life-
threatening infection with a high mortality. Survival can be improved by implementing 
quality of care bundles in hospitals. We previously observed marked differences in mortality 
between hospitals and now assessed whether mortality could serve as a valid and easy to 
implement quality of care outcome measure. 
Methods: We conducted a prospective observational study between January 2013 and April 
2015 on consecutive, adult patients with SAB from 11 tertiary care centers in Germany, 
South Korea, Spain, Taiwan, and the United Kingdom. Factors associated with mortality at 
90 days were analyzed by Cox proportional hazards regression and flexible parametric 
models. 
Results: 1,851 patients with a median age of 66 years (64% male) were analyzed. Crude 90-
day mortality differed significantly between hospitals (range 23% to 39%). Significant 
variation between centers was observed for methicillin-resistant S. aureus, community-
acquisition, infective foci, as well as measures of comorbidities, and severity of disease. In 
multivariable analysis, factors independently associated with mortality at 90 days were age, 
nosocomial acquisition, unknown infective focus, pneumonia, Charlson comorbidity index, 
SOFA score, and study center. The risk of death varied over time differently for each 
infective focus. Crude mortality differed markedly from adjusted mortality. 
Discussion: We observed significant differences in adjusted mortality between hospitals, 
suggesting differences in quality of care. However, mortality is strongly influenced by patient 
mix and thus, crude mortality is not a suitable quality indicator. 
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Introduction 
Staphylococcus aureus is one of the commonest causes of nosocomial and community-
acquired bloodstream infection (1). The associated mortality is substantial and varies between 
20-30% at 90-days (2). Considerable efforts, including the use of quality targets, have been 
made in many healthcare systems to reduce the incidence and burden of S. aureus infection, 
and particularly of methicillin-resistant S. aureus (MRSA). 
We have previously reported a pooled analysis of five prospective studies including 3395 
patients with S. aureus bloodstream infection (SAB) from 20 hospitals in Europe and the 
USA and found marked differences in outcome between centers (3). Such differences might 
reflect variations in the quality of care received by patients with SAB, or alternatively, be the 
result of varying patient populations with different characteristics and access to hospital care 
and/or local variations in the prevalence of different S. aureus strains. 
The impact of patient, pathogen, and management factors on outcome of SAB has been 
widely studied. Major patient factors include age, burden of comorbid disease, and the nature 
of the infective focus. Pathogen factors have been associated with particular disease 
manifestations (e.g. device related bacteremia) (4,5). Management of SAB is challenging and 
has been described as a major determinant of outcome. Choice of empiric and definitive 
therapy, extent of diagnostic investigation, source control, and duration of treatment are all 
identified as independent determinants of survival (6,7). Several studies have demonstrated 
the advantage of involving infection specialists and use of management bundles (8–10). 
Quality measures have permeated medicine and are increasingly used for accountability and 
reimbursement. The measures inventory of the Center for Medicare and Medicaid Services in 
the United States lists several process measures concerning SAB (11). The National Health 
Service (NHS) in the United Kingdom employs the incidence of MRSA to compare 
healthcare-associated infection between hospitals (12). Although mortality of SAB is 
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currently not measured, comparable outcome measures are used in other disease areas. For 
example, mortality from breast cancer in females or mortality within 30 days of hospital 
admission for stroke are current NHS digital indicators (12). 
Our objective was therefore to investigate whether crude mortality could serve as an 
objective and easy to implement quality indicator. In a multicenter, multinational, 
prospective, observational study on consecutive patients with SAB, we assessed between-
center differences in mortality and how these differences are influenced by patient and 
disease factors. 
 
 
Methods 
Study design 
We conducted a prospective, multicenter, international cohort study (ISAC-01 study, 
ClinicalTrials.gov identifier NCT02098850) in 11 tertiary care hospitals across 5 countries: 
Germany (2 centers), Korea (1 center), Spain (2 centers), Taiwan (1 center), and the United 
Kingdom (5 centers). All centers collected data on at least 80 consecutive patients with SAB. 
 
Ethics approval 
Ethics approval was obtained at each study center according to local regulations. Informed 
consent was sought from patients for follow-up visits. In some centers the study was 
conducted as part of a service evaluation and informed consent was waived by the Ethics 
Review Committee or relevant national authority. 
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Participants 
Consecutive hospitalized patients with S. aureus cultured from blood between 01 January 
2013 and 30 April 2015 were enrolled, unless bacteremia represented contamination as 
judged by an infectious diseases physician or clinical microbiologist. Patients with a previous 
episode of SAB within the prior 12 weeks and patients with polymicrobial bacteremia (except 
common skin contaminants) were excluded. 271 participants from the UK centers were co-
enrolled in the “Adjunctive rifampicin for Staphylococcus aureus bacteremia (ARREST)” 
trial (EudraCT No. 2012-000344-10) (13); their data was provided from the ARREST trial 
database as the trial case report forms were shared. 
 
Study size and Bias 
Data collection was initially planned for a minimum of 2 years aiming for approximately 
2,000 patients in the overall cohort. To avoid selection bias, only consecutive cases from 
centers with a minimum of 80 participants during the study period were included in this 
analysis. Each participating center regularly checked recruitment against their own hospital’s 
laboratory reporting data to ensure cases were not missed. Information bias was avoided by 
agreeing a unified case report form applying the same definitions for the ISAC-1 and 
ARREST study patients. 
 
Collected data 
Data were prospectively collected by dedicated medical staff and reviewed by an infectious 
disease physician or clinical microbiologist. Data were collected during infectious disease 
consultations, patient visits, and from patient charts or registries. Factors measured comprised 
basic demographic data (age, gender) and comorbidity (Charlson comorbidity index [not age-
adjusted] (14) and injecting drug use). We chose the Sepsis-related Organ Failure Assessment 
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(SOFA) score (15) to measure the severity of infection at the time the first positive blood 
culture was obtained. Mode of acquisition of SAB was categorized with slight variations to 
the Friedman criteria (16). When SAB onset (i.e. systemic signs of SAB or the first positive 
blood culture in the absence of systemic signs) occurred after more than 48hrs of hospital 
admission, SAB was classified as “nosocomial”. When less than 48hrs after hospital 
admission had elapsed, patients were classified as “community-onset healthcare-associated” 
if there was a significant history of healthcare contact (defined as regularly receiving 
intravenous therapy or specialized wound care at home, or receiving hemodialysis or 
intravenous chemotherapy within 30 days, hospitalized for more than 1 day in the previous 
90 days, residence in nursing-home or long-term care facility). The remaining patients were 
classified as “true community-acquired”. 
The infective focus was defined as the site of infection most likely to be responsible for 
seeding into the bloodstream, categorized into nine groups: endocarditis, osteoarticular (bone 
and joint infection with and without prosthetic device), pneumonia, skin and soft-tissue, 
surgical wounds, central venous catheter, peripheral venous catheter, and “other deep focus”; 
a substantial minority of foci were unknown. A hierarchical ranking of the infective focus 
(dominant focus) was established for multiple foci as defined previously (3,17), namely: 
endocarditis > osteoarticular > pneumonia > other deep focus > surgical wound > skin and 
soft-tissue > central venous catheter > peripheral venous catheter. 
The primary outcome measure was survival through 90 days. Patients were followed-up by 
either in-person visits to the hospital, or by telephone. Where possible, survival data were 
confirmed by national death registry data. Patients lost to follow up were censored at the date 
of their last visit or last known date of interaction with healthcare (if available). 
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Statistical Methods 
Categorical data were described by count and percentage, quantitative data as median and 
interquartile ranges, and compared between centers using Kruskal-Wallis and chi-squared 
tests for continuous and categorical data respectively. To investigate predictors of survival 
following SAB, we used Cox proportional hazards regression models including: age, gender, 
MRSA (vs methicillin-susceptible SAB), mode of acquisition (nosocomial, community-onset 
healthcare-associated, or true community-acquired), injecting drug use, comorbidity 
(Charlson comorbidity index), disease severity (SOFA score), dominant focus as described 
above, and study center. Charlson and SOFA scores were truncated at their 99th percentiles 
(10 and 17 respectively) to avoid undue influence from outliers. There was no evidence of 
non-linearity in the effect of any continuous factor (age, Charlson, SOFA) in multivariable 
models, assessed using multivariable fractional polynomials. Given the number of possible 
interactions between these factors, those with p<0.001 were included based on forward 
selection. 
To estimate how the risk of mortality varied over time, a flexible parametric model (18) was 
also fitted to the data including the same factors and interactions as the final Cox model 
above, with the hazard as the underlying time scale to produce comparable hazard ratios. The 
underlying survival function for this model is based on natural cubic splines and the number 
of internal knots for the spline was chosen by minimizing the Bayesian Information Criterion 
(BIC). A single internal knot (at the 50th percentile of death times) was selected. Time-
varying coefficients were included for dominant focus and SOFA based on improvements to 
the BIC. As the time-varying effects of SOFA were small in magnitude, we also considered 
time-varying coefficients for dominant focus and center to explore center effects. 
All statistical analyses were performed in R, version 3.2.2 (R Development Core Team), in 
particular the rstpm2 package, version 1.3.4, and Stata version 15.1. 
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Role of the funding source 
The ISAC-01 study did not receive dedicated funding. Funding for data acquisition of 
patients that were also enrolled in the ARREST study was provided by UK National Institute 
for Health Research Health Technology Assessment. The funding organizations had no 
influence on the design of the study, the collection, analysis, and interpretation of the data; 
and the decision to approve publication of the finished manuscript. 
 
 
Results 
In total, 2,080 patients met criteria for inclusion into the study and had complete evaluable 
data. 1,809 patients were recruited from ISAC-01 and 271 from ARREST. 145 patients were 
then excluded as SAB was found as part of a polymicrobial infection, and 84 were excluded 
as they had a documented prior episode of SAB in the 12 weeks prior to screening. A total of 
1851 cases were therefore evaluated in the final analysis (Figure 1). 
 
Patient Characteristics 
Clinical and demographic variables are shown for each study center (Table 1). Median age 
was 66 years (IQR 52–77) and 1181 (64%) patients were male. There were highly significant 
between center differences (p<0.0001) in patient age, prevalence of MRSA, mode of 
acquisition, burden of comorbid disease as assessed by Charlson comorbidity index (CCI), 
proportion of patients injecting drugs, and severity of illness as determined by SOFA score 
(Table 1). Other than surgical wounds and endocarditis, there were marked differences 
between centers in the distribution of infective foci identified. Overall 370 cases (20%) had 
no infective focus identified; this varied substantially between centers (8%–33%). 
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MRSA was present in 302 (16%) patients. Of these 135 (45%) were nosocomial infections, 
114 (38%) were community-onset healthcare-associated, and 53 (18%) were true community-
acquired infections (p<0.0001 vs MSSA). Patients with MRSA were older (median 70 vs 65 
years respectively, p=0.0001), had higher disease severity (median SOFA 5 vs 3 respectively, 
p=0.0001), and higher comorbidity (median CCI 3 vs 2, p=0.0001), and were less likely to be 
injecting drugs (4/302 (1%) vs 100/1549 (6%), p<0.0001). 
 
Outcome 
Both early mortality (death within 72 hours of first positive S. aureus blood culture) and 
overall mortality (death within 90 days) differed significantly between study centers (Figure 
2(a)). Overall, 132 patients (7%) died within 72 hours (between-center range 4–14%, chi-
squared p=0.03); and 563 (30%) patients died by day 90 (range 23–39%, chi-squared 
p=0.004).  
Mortality also varied markedly depending on the dominant infective focus (Figure 2(b)). The 
highest mortality occurred in patients with pneumonia (87 cases, 54% mortality), followed by 
unknown focus (172 cases, 46%), and endocarditis (41 cases, 31%). Lowest mortality 
occurred in patients with peripheral venous catheter (27 cases, 18%) and osteoarticular 
infections (51 cases, 19%). Overall the median duration of hospitalization was 18 days (IQR 
9–31 days) following first positive S. aureus blood culture; this varied significantly 
(p<0.0001) between centers (range 12–21 days). 
 
Predictors of Survival at 90 days 
The association between demographic and clinical factors and overall mortality by 90 days is 
shown in Table 2. Besides pneumonia and “unknown” infective focus, crude (unadjusted) 
mortality was associated with older age, not using injecting drugs, nosocomial or healthcare-
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associated acquisition, higher comorbidity, and more severe disease. There was significant 
variation in crude 90-day mortality across centers (range 23-39%, p=0.004; Table 1 and 
Figure 3). 
In multivariable models (Table 2), all these factors except injecting drug use remained 
significantly associated with mortality. There was strong evidence of interactions between 
age and CCI (p=0.0006) and SOFA and CCI (p=0.0003) (Supplementary Figure 1), such that 
the substantially increased risk associated with greater values of each of them was attenuated 
(i.e. reached a threshold) if patients had high values of all of them. Increases in SOFA score 
had a particularly marked effect on mortality risk in patients without comorbidities 
(Supplementary Figure 1(b)): increasing SOFA score changed risk much less in those with 
substantial comorbidities. The multivariable model confirms that patients with pneumonia 
(hazard ratio, HR=2.28, 95% CI 1.58–3.29, p<0.0001), unknown infective focus (HR=2.36, 
95% CI 1.70–3.27, p<0.0001) had significantly higher mortality than those with central lines 
or another dominant focus (Table 2). 
The crude mortality risk estimates relative to center-1 and the adjusted estimates (adjusted for 
clinical and demographic factors and interactions between them) were substantially different, 
both quantitatively and qualitatively (Figure 3). Among five centers (centers 2,4,7,8,9) with 
crude relative-risk point estimates substantially lower than the reference, adjustment brought 
three back to near 1 but hardly affected two, one of which remained statistically significantly 
less than center 1. Conversely, for two centers (3 and 10) which had crude relative-risk point 
estimates near 1, adjustment revealed significantly higher mortality risks. When deaths within 
the first three days were excluded to account for differences in the early management of 
infection or late clinical presentation of patients, the mortality effect in center 10 was 
reduced, but remained significant (Supplementary Table 1).  
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The Cox model estimates an overall “average” association with mortality that is proportional 
for each factor over time from the first positive blood culture (similar to the “average” 
produced from a logistic model), whereas Figure 2(b) suggests that the mortality associated 
with infective foci may vary differently. Thus, we estimated how mortality risk varied over 
time from the first positive blood culture drawn according to dominant infective focus (and 
SOFA score) using multivariable flexible parametric models (Figure 4). The overall higher 
mortality risk identified in patients with pneumonia and unknown infective focus was driven 
by very high mortality within the first weeks, which dropped to approach that of other deep 
foci by day 42; over the longer-term, all deep foci had similar mortality. In contrast long-term 
mortality risk was much lower for superficial foci (peripheral lines), and intermediate for 
those with central lines and skin and soft tissue infections. There was also evidence, as might 
be expected, that the impact of higher baseline SOFA scores decreased with time from 
positive blood culture (p=0.0001; Supplementary Figure 2). However, these additional 
improvements to the model were small in magnitude and did not alter the center effects 
(Figure 3). Models allowing both focus and center effects to vary over time (rather than focus 
and SOFA score) suggested that differences between centers were greatest early in the 
disease course (Supplementary Figure 3). 
 
Discussion 
We have previously noted striking differences in SAB case-fatality rates between hospitals 
(3). To investigate the reasons for these differences requires a substantial unbiased patient 
cohort that supports adjustment for multiple confounding patient and disease factors. 
Therefore, we conducted a large, international, observational cohort study of SAB to 
determine whether differences in survival between treatment centers are most likely 
explained by patient factors and type of infection, or whether they persist after adjustment 
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suggesting that they might be due to clinical interventions, and therefore be regarded as a 
measure of institutional quality. 
To summarize all measures related to the management of infection, we introduced “center” as 
a factor in the analysis. We confirmed the previously observed marked differences in crude 
90-day mortality. However, center effects were generally smaller than the effects of 
pneumonia as the infective focus and an “unknown” infective focus. When adjusting for 
confounders in a Cox regression model, center effects changed markedly compared to crude 
estimates. Thus, variations in case-mix may outweigh the effect of infection management on 
a hospital level. We therefore conclude that hospital-wide crude mortality is not suitable as an 
indicator of organizational quality of care. 
There is little doubt that quality of care influences outcome on the individual patient level in 
patients with SAB and it has been shown that achievement of quality measure indicators can 
improve outcome (10). However, as shown here, the crude mortality rate is strongly 
influenced by other factors. In a complex and heterogenous disease like SAB, the link 
between a quality intervention and outcome may be weak. For example, taking follow-up 
blood cultures may be vital in some patients to detect infective endocarditis, but less 
important in other patients with peripheral venous catheter infection. Likewise, early 
antibiotic therapy may be more effective in patients with severe comorbidities than in patients 
without comorbidities (19). 
From clinical experience, we expected that the risk of death could vary over time for different 
infective foci. Indeed, several different dynamics could be identified using flexible 
parametric models that account for this (Figure 4). For example, mortality in patients with 
pneumonia and unknown foci was greatest shortly after SAB onset, converging to a similar 
long-term mortality risk as other deep foci. In contrast, patients with endocarditis had a lower 
initial mortality risk, potentially reflecting the time it takes for S. aureus to destroy the heart 
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valves and/or cause clinically relevant foci at distant sites. Superficial foci, such as line 
infections, had a substantially lower ongoing mortality risk than deep-seated foci. This 
difference confirms the clinical observation that deep-seated infection is a more serious 
disease entity and may reflect unaddressed reservoirs of infection or sequelae of SAB. In the 
case of “unknown focus”, however, we cannot rule out that early mortality is driven by a lack 
of time for correctly diagnosing the underlying focus in severely ill patients. 
This study was designed to remedy limitations of our previous post-hoc analysis, for example 
by including data on comorbidities and illness acuity (3). The strengths of the study are its 
size, the comprehensive, prospective collection of data from consecutive patients including 
details of comorbidity, severity of disease, and clinical course, with very little missing data. 
We also included hospitals from different healthcare systems that should increase the 
likelihood of observing the impact of different hospital care delivery models on outcome 
from an infectious disease. 
Nevertheless, limitations remain. Important risk factors or confounders may have been 
missed. For example, we have not assessed the impact of pathogen factors beyond methicillin 
resistance. Previous studies have reported decreased (20) or similar (21) survival rates in 
patients infected with MRSA. Although, in the univariable analysis MRSA was associated 
with a higher mortality, the effect was lost when adjusting for confounders. This may be 
explained by the fact that patients with MRSA were older, had more severe comorbidity, and 
a higher severity of disease. Previous studies which have attempted to determine the impact 
of pathogen factors on outcome of SAB indicate that effects are variable between different 
clonal lineages and multi-locus sequence types. However, the effects are likely to be small in 
comparison to patient and management factors (4,22). 
Furthermore, if there were differences in the detection of SAB between hospitals (e.g. by 
different policies governing when to take blood cultures) or if patients present themselves at 
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later disease stages (e.g. due to differences in healthcare systems), this could have introduced 
a bias into the analysis if it were related to factors other than those we already adjusted for. 
We are not aware of such differences but cannot exclude them. Lastly, whilst centers 
included all patients treated for SAB, we cannot exclude the possibility that patients on end-
of-life pathways were managed differently in different hospitals in terms of active antibiotic 
treatment. Finally, the need to perform detailed prospective assessment of patients resulted in 
our study being performed in large, tertiary teaching centers with specialist infectious 
diseases teams. It is possible that these centers all have similarly high standards of 
management for S. aureus infection, which may limit generalizability of our results. To 
further explore which measures and interventions can reduce the mortality of SAB, a detailed 
study should be performed on multiple hospitals from the same healthcare system across 
different levels of care. 
Using a large prospective cohort, we have identified substantial differences between study 
centers in mortality following SAB. However, adjustment for patient factors at baseline 
including age, burden of comorbid diseases, infective focus, mode of acquisition, and disease 
severity did markedly change the effect of “center” on mortality. Therefore, crude mortality 
is not a valid quality of care outcome measure and should not be used to guide hospital 
reimbursement. 
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